Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 4/20 | 0.39 |
| ▸ | ADH1C | P00326 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329799 | 0.87 | — | — | |
| SCHEMBL22212617 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL20733077 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL20725618 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL23374154 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL23072499 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL23072500 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL24914755 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL22764966 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL | |
| SCHEMBL20725627 | 0.84 | ADH1A (0.50) | ADH1AADH1CFAAHPHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |